Bioptix, Inc. (NASDAQ:BIOP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
agreement with Richard J. Whitcomb, (the “Separation
Agreement”), providing for Mr. Whitcomb’s separation as Senior
Vice President, Corporate Development of the Company, effective
June 15, 2017. Mr. Whitcomb’s separation was not the result of
any disagreement with the Company, any manner related to the
Company’s operations, policies or practices, the Company’s
management or the Board. The Separation Agreement is attached
hereto as Exhibit 10.1 to this Form 8-K and is incorporated
herein by reference.
part of this Current Report on Form 8-K.
|
Exhibit No.
|
Description
|
||
|
10.1
|
Form of Separation Agreement dated as of June 15, 2017
|
||
About Bioptix, Inc. (NASDAQ:BIOP)
Bioptix, Inc., formerly Venaxis, Inc., provides Enhanced Surface Plasmon Resonance (SPR) platform for the detection of molecular interactions. The Company’s line of Enhanced SPR instruments are designed to increase the flexibility and reliability of SPR. Its SPR biosensors shed light on important binding parameters that are crucial for determining whether a biologic or small molecule drug will be efficacious in humans and at what dose a drug should be administered. Its technology is an ultra-sensitive detection platform. The design of its SPR spectrometers allows discrete areas within the sample cell to be interrogated simultaneously by use of photo-diode arrays aligned to the reflected beam from the sample cell. Its biosensors provide information on kinetic processes (association and dissociation), binding affinities, analyte concentrations and real-time molecule detection. The Company offers 404pi Enhanced SPR System, which enables real-time detection of biomolecular interactions.
